ArticleFrontiers in oncology2025
A robust ammonia metabolism gene signature identified by machine learning predicts prognosis and immunotherapy response in clear cell renal cell carcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immunometabolic Stress and Immune Suppression in Clear-Cell Renal Cell Carcinoma: Perspectives in Therapeutic Strategy.International journal of molecular sciences · 2026Review
- Ammonia metabolic reprogramming in the tumor microenvironment: emergence of an immunosuppressive niche.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite the widespread use of immune checkpoint inhibitors (ICIs) in advanced clear cell renal cell carcinoma (ccRCC), therapeutic resistance persists. The prognostic and immunomodulatory role of ammonia metabolism remains unclear. Methods: We leveraged public RNA-seq data and machine learning to identify ammonia metabolism pathways through enrichment analysis of programmed cell death-related genes. Employing multi-omics data from ccRCC patients, we developed an ammonia metabolism risk score (AMRS) via machine learning, which was validated externally and in immunotherapy cohorts. Additionally, scRNA-seq, WGCNA, TMB analysis, and Results: From 147 prognostic ammonia metabolism-related genes in TCGA, a 4-gene random forest model was constructed using LASSO and multivariate Cox regression. This model demonstrated robust predictive accuracy in external validation (3/5/7-year AUCs: 0.710/0.721/0.771). High-risk patients showed significantly elevated mortality in external cohorts (HR = 4.23, 95% CI 1.57-11.42, p = 0.002) and multiple ICI cohorts (HR = 1.30-1.69, p < 0.05). Functional validation via CSAD-targeted siRNA knockdown suppressed migration and invasion by >44% (p < 0.05) across four ccRCC cell lines. Conclusions: Our integrated approach overcomes modeling constraints from limited samples and high-dimensional data and establishes a novel ammonia metabolism-related prognostic signature for ccRCC. CSAD emerges as a promising biomarker warranting further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.